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Abstract 
Importance. Deaths among patients with coronavirus disease 2019 (COVID-19) are partially 
attributed to venous thromboembolism and arterial thromboses. Anticoagulants prevent 
thrombosis formation, possess anti-inflammatory and anti-viral properties, and may be 
particularly effective for treating patients with COVID-19. 
 
Objective. To evaluate whether initiation of prophylactic anticoagulation within 24 hours of 
admission is associated with decreased risk of death among patients hospitalized with COVID-
19. 
 
Design. Observational cohort study. 
 
Setting. Nationwide cohort of patients receiving care in the Department of Veterans Affairs, the 
largest integrated healthcare system in the United States. 
 
Participants. All patients hospitalized with laboratory-confirmed SARS-CoV-2 infection March 1 
to July 31, 2020, without a history of therapeutic anticoagulation. 
 
Exposures. Prophylactic doses of subcutaneous heparin, low-molecular-weight heparin, or 
direct oral anticoagulants.  
 
Main Outcomes and Measures. 30-day mortality. Secondary outcomes: inpatient mortality and 
initiating therapeutic anticoagulation.  
 
Results. Of 4,297 patients hospitalized with COVID-19, 3,627 (84.4%) received prophylactic 
anticoagulation within 24 hours of admission. More than 99% (n=3,600) received subcutaneous 
heparin or enoxaparin. We observed 622 deaths within 30 days of admission, 513 among those 
who received prophylactic anticoagulation. Most deaths (510/622, 82%) occurred during 
hospitalization. In inverse probability of treatment weighted analyses, cumulative adjusted 
incidence of mortality at 30 days was 14.3% (95% CI 13.1-15.5) among those receiving 
prophylactic anticoagulation and 18.7% (95% CI 15.1-22.9) among those who did not. 
Compared to patients who did not receive prophylactic anticoagulation, those who did had a 
27% decreased risk for 30-day mortality (HR 0.73, 95% CI 0.66-0.81). Similar associations were 
found for inpatient mortality and initiating therapeutic anticoagulation. Quantitative bias analysis 
demonstrated that results were robust to unmeasured confounding (e-value lower 95% CI 1.77). 
Results persisted in a number of sensitivity analyses. 
 
Conclusions and Relevance. Early initiation of prophylactic anticoagulation among patients 
hospitalized with COVID-19 was associated with a decreased risk of mortality. These findings 
provide strong real-world evidence to support guidelines recommending the use of prophylactic 
anticoagulation as initial therapy for COVID-19 patients upon hospital admission.  
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Background 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes 
coronavirus disease 2019 (COVID-19), continues to spread worldwide. Deaths among 
individuals with COVID-19 have been partially attributed to venous thromboembolism and 
arterial thromboses.1,2 In intensive care settings, prevalence of venous thromboembolism 
among patients with COVID-19 has been reported to be over 40%.3 In response, several expert 
organizations including the American Society of Hematology, the International Society on 
Thrombosis and Haemostasis, and the CHEST Guideline and Expert Panel have recommended 
the use of prophylactic anticoagulation for patients admitted with COVID-19 who do not have a 
contraindication to this therapy.1,4,5   
The most commonly used anticoagulants in hospital settings are heparin-based. Given these 
drugs also possess anti-inflammatory properties,6–8 heparin-based therapies may be particularly 
effective in treating patients with COVID-19.9 Evaluations of the efficacy of prophylactic 
anticoagulation in COVID-19 patients in randomized clinical trials are underway but yet to be 
reported.10 Previous observational cohort studies have shown evidence that use of 
anticoagulation in COVID-19 patients was associated with decreased risk of mortality;11,12 
however, these studies were limited in sample size or relatively small healthcare systems. Our 
objective was to estimate the effect of early initiation of prophylactic anticoagulation on the risk 
of 30-day mortality among patients hospitalized with COVID-19 in the largest integrated 
healthcare system in the United States.  
 
Methods 
Study design and population 
We conducted an observational cohort study using electronic health record (EHR) data from the 
US Department of Veterans Affairs (VA), which comprises over 1,200 points of care nationwide 
including hospitals, medical centers, and community outpatient clinics. All care is recorded in an 
EHR with daily uploads into the VA Corporate Data Warehouse. Available data include 
demographics, outpatient and inpatient encounters, diagnoses, procedures, smoking and 
alcohol health behaviors, pharmacy dispensing records, vital signs, laboratory measures, and 
death information. 
 
We included all patients hospitalized between March 1 and July 31, 2020 who had a laboratory-
confirmed positive SARS-CoV-2 test result on or within 14 days prior to hospital admission. We 
excluded patients who had no history of care (defined as at least one outpatient or inpatient 
encounter in the two years prior to March 1, 2020), received therapeutic anticoagulation in the 
30 days prior to hospital admission (to mitigate the effect of prevalent use of anticoagulation), 
received a red blood cell transfusion with 24 hours of admission (as active bleeding or severe 
anemia may have been a contraindication for anticoagulation), or experienced any of the 
primary outcomes (i.e., died or initiated therapeutic anticoagulation) within 24 hours of 
admission and therefore did not have equal chance to be classified as exposed in this study. 
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Forms and doses of anticoagulation 
We extracted inpatient pharmacy records for warfarin, intravenous heparin, low-molecular-
weight heparin (LMWH; i.e., enoxaparin, fondaparinux, dalteparin), and direct oral 
anticoagulants (DOAC; i.e., apixaban, rivaroxaban, dabigatran). Doses and routes considered 
prophylactic anticoagulation are listed in Box 1. Any dose higher than these levels, in addition to 
warfarin at any dose, were considered therapeutic anticoagulation. 
 
Box 1. Agents and doses of prophylactic anticoagulation   
Type Drug Route Prophylactic dose Observed in sample 
Heparin Heparin SC 5000 units b.i.d. or t.i.d. 1094 (30.2%) 
LMWH Enoxaparin SC 40 mg q.d. or 30 mg  b.i.d. 2506 (69.1%) 
LMWH Fondaparinux SC 2.5 mg q.d. 4 (0.1%) 
LMWH Dalteparin SC 2500-5000 units q.d. - 
DOAC Apixaban Oral 2.5 mg b.i.d. 21 (0.6%) 
DOAC Rivaroxaban Oral 10 mg q.d. or 2.5 mg b.i.d. for 
arterial disease 
2 (0.1%) 
DOAC Dabigatran Oral 220 mg q.d. - 
Abbreviations: q.d., once daily; b.i.d., twice daily; t.i.d., thrice daily; SC, subcutaneous; 
LMWH, low-molecular-weight heparin; DOAC, direct oral anticoagulant 
 
Exposure, outcomes, and follow-up 
The exposure of interest was receipt of prophylactic anticoagulation in the first 24 hours of 
hospitalization compared to no receipt of prophylactic anticoagulation in the same time frame. 
Primary outcome was mortality within 30 days of hospital admission (“30-day mortality”), which 
included in-hospital deaths as well as those that occurred after discharge. Secondary outcomes 
were inpatient mortality and initiation of therapeutic anticoagulation. Algorithms to identify 
thromboembolic events during hospitalizations of COVID-19 patients have yet to be validated; 
thus, we considered initiation of therapeutic levels of anticoagulation after the first 24 hours of 
admission a proxy for a thromboembolic event. For all outcomes, we followed patients from date 
of hospital admission until earliest of date of outcome or a maximum of 30 days.  
 
Some VA hospitals report observation periods and admissions separately, even when a patient 
has not moved beds or changed providers. We combined these periods and considered a full 
hospitalization to begin at first presentation in a VA hospital and end when there was not a 
subsequent “stay” that began within 24 hours. Study design is depicted in Figure 1. 
 
Covariates 
Potential confounders in the relationship between receipt of anticoagulation and COVID-19 
mortality or thromboembolic events were identified by reviewing existing literature and through 
discussions with clinicians. We extracted information on age, race/ethnicity, sex, urban/rural 
residence, US Census region, clinical comorbidities, Charlson Comorbidity Index, and 
substance use. Presence of clinical comorbidities was determined by one inpatient or two 
outpatient diagnoses using International Classification of Diseases - 9th or 10th edition (ICD-
9/10) codes in the two years prior to hospitalization, except for cancer, which was considered 
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present if diagnosed ever prior to hospitalization. Level of alcohol consumption was calculated 
using the most recent Alcohol Use Disorder Identification Test - Consumption (AUDIT-C)13 
measure within two years prior to admission. Smoking status was determined by the most 
frequent response in the five years prior to hospitalization.14  
 
We ascertained medication history in the 15 to 90 days prior to hospitalization. We captured 
vital signs and laboratory measures to account for acute health status at hospital admission. 
Height and weight measurements closest to hospitalization within five and two years, 
respectively, prior to admission were used to calculate body mass index. All other vital signs 
and all laboratory measures utilized the value closest to hospitalization within 14 days prior to 




To account for potential effects of co-medications with other COVID-19 treatments, we 
ascertained receipt of oral or intravenous dexamethasone15 at any dose or intravenous 
remdesivir16 at any dose within the first 24 hours of hospitalization as well as treatments 
received after the first 24 hours.  
 
Covariates with the largest proportion of missing data included alanine aminotransferase 
(13.5%), aspartate aminotransferase (15.2%), lymphocyte count (15.0%), and total cholesterol 
(14.1%): all other covariates had <10% missing.  
Index date (Hospital admission) End of follow-up
Covariates: 
Acute myocardial infarction, alcohol consumption, alcohol use disorder, asthma, 
BMI, cerebrovascular disease, cholesterol, chronic kidney disease, COPD, 
coronary artery disease, dementia, diabetes, heart failure, hypertension, liver disease, 
peripheral arterial disease, Charlson Comorbidity Index, [-2y,-15d]
Cancer [-∞,-15d]
Smoking status [-5y,-15d]
Exposure ascertainment window: 
Prophylactic anticoagulation [0,24h]
Time
Inclusion: Positive PCR COVID-19 test [-14d,0]
Outcomes [24h,30d]: 
30-day mortality, inpatient mortality, 
initiate therapeutic anticoagulation
Exclusion: Receipt of therapeutic anticoagulation [-30d,0]
Covariates: 
ACE inhibitor, ARB, NSAID, 
oral corticosteroid [-90d,-15d]
Abbreviations: h, hour; d, day; m, month; y, year; BMI, body mass index; COPD, chronic obstructive pulmonary disease; ACE, angiotensin converting enzyme; ARB, 
angiotensin II receptor blocker; NSAID, non-steroidal anti-inflammatory drug; PCR, polymerase chain reaction; RBC, red blood cell
Notes: End of follow-up for all outcomes was earliest of: date of outcome, a maximum of 30 days, or August 30, 2020. For the analysis of inpatient mortality and 
initiating therapeutic anticoagulation, we further censored patients at date of hospital discharge.




Age, race/ethnicity, sex, urban/rural residence, census region [0,0]
Covariates: 
Labs (i.e., alanine/aspartate aminotransferase, estimated glomerular filtration rate, 
glucose, haemoglobin, platelet count, white blood cell count, lymphocyte count), 
vitals (i.e., oxygen saturation, pulse, systolic blood pressure, temperature) [-14d,-0]
Exclusion: 
Outcome, RBC transfusion, or 
discharged from hospital [0,24h]
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Propensity score model 
We used inverse probability of treatment (IPT) weighting to estimate the marginal treatment 
effect. We first modeled the probability of receiving the exposure of interest as a function of all 
measured covariates (apart from in-hospital treatments received after the first 24 hours so as to 
not use future information at baseline).17 Propensity scores (i.e., the predicted probability of 
exposure) were estimated using a multivariable logistic regression model. We included a 
missing category for covariates with missing data. The area under the receiver operating 
characteristic curve was 0.74. Each patient was weighted by the inverse probability of receiving 
the exposure of interest, with the goal of balancing observable characteristics between 
treatment groups. After IPT weighting, the distribution of propensity scores between the 
treatment groups overlapped nearly perfectly (eFigure 1). We calculated absolute standardized 
mean differences between treatment groups and considered ≤0.2 as balanced,18 although the 
vast majority were ≤0.1 (eFigure 2). Thus, the weighting produced treatment groups that were 
considered well balanced. 
 
Statistical methods 
Covariates were summarized using descriptive statistics, stratified by treatment group. We 
generated IPT-weighted Kaplan Meier plots. We used Cox regression models with days since 
hospital admission as the timescale to estimate IPT-weighted hazard ratios (HRs) and 95% 
confidence intervals (CIs) for the effect of early initiation of prophylactic doses of anticoagulation 
on 30-day mortality, inpatient mortality, and initiating therapeutic anticoagulation. Both 
secondary outcomes occur during hospitalization, wherein discharge from hospital was 
considered a competing event. If patients were censored at discharge, absolute risks derived 
from Kaplan-Meier analyses would be overestimated.19,20 We therefore displayed cumulative 
adjusted incidence rates by treatment group treating discharge as a competing event (i.e., no 
censoring at date of discharge). We nonetheless chose to display cause-specific rather than 
sub-distribution hazard ratios as our question was etiological in nature.21 These cause-specific 
hazard ratios were interpreted as the effect of prophylactic anticoagulation on each of the 
outcomes irrespective of its effect on discharge. Proportional hazards were checked by 
examining the complementary log-log (or the log of negative log) of estimated survivor functions 
for exposed and unexposed groups versus the log of survival time. There was no evidence of 
proportional hazards violations.  
 
Sensitivity analyses 
For each outcome, we used quantitative bias analysis to calculate an e-value, which 
demonstrates the strength of association between an unmeasured confounder and exposure or 
outcome, conditional on measured covariates, that would be necessary to fully explain observed 
effects.22 To assess for undue effects from outliers with very high or very low estimated 
propensity of treatment, we capped propensity score distributions at the 1st/99th and again at the 
5th/95th percentiles. To account for potentially biased estimation of standard errors or influence 
from very high or very low weights, we performed sensitivity analyses using combinations of 
robust standard error estimation23 and stabilized weighting.24 We re-ran the primary analyses 
extending the exposure ascertainment window from 24 to 48 hours. Given the low frequency of 
DOAC use in the cohort, we re-ran analyses excluding DOACs from the exposure definition. In 
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post-hoc analyses, we assessed the effect of prophylactic anticoagulation separately by the two 
most commonly prescribed drugs in the cohort, heparin and enoxaparin. We used Microsoft 
SQL Server Management Studio v17.4 for data management and SAS version 9.4 (SAS 
Institute, Cary, NC, US) and Stata 16 MP for statistical analyses. 
 
Ethics 
This study was approved by the institutional review boards of VA Connecticut Healthcare 
System and Yale University. It has been granted a waiver of informed consent and is Health 
Insurance Portability and Accountability Act compliant. This study is reported as per the 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and 
REporting of studies Conducted using Observational Routinely collected health Data for 




We identified 4,297 patients hospitalized with COVID-19 between March 1 and July 31, 2020 





Figure 2. Flow chart
All patients hospitalized between 
March 1 and July 31, 2020 
with history of care in VA
N = 141,839
Tested negative/not in eligible window
N = 107,065
No therapeutic anticoagulation in 30 
days prior to admission
N = 5,025
Abbreviations: VA, US Department of Veterans Affairs; COVID-19, coronavirus disease 2019; RBC, red 
blood cell
Laboratory-confirmed positive test on or 
within 14 days prior to hospitalization
N = 5,547
Therapeutic anticoagulation in 
30 days prior to admission
N = 522
Outcome or RBC transfusion 
within 24 hours of admission
N = 728




Patients with a COVID-19 test
N = 112,612
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Median age in the cohort was 68 years (interquartile range [IQR] 58-75); most were non-
Hispanic Black (n=1,940, n=45.1%), non-Hispanic White (n=1,603, 37.3%), or Hispanic (n=506, 
11.8%). The majority were male (n=4,015, 93.4%), geographically located in the South 
(n=2,017, 46.9%), and lived in an urban area (n=3,768, 87.7%) (Table 1). By month, most 
patients were hospitalized in July (n=1,401, 32.6%).  
 
Table 1. Demographic and clinical characteristics of 4,297 hospitalized patients with COVID-19 by exposure to 
prophylactic dose of anticoagulation (AC) within 24 hours of admission, before and after weighting 
 Unweighted  IPT-weighted 
  No AC AC SMD   No AC AC SMD 
Sample size, n 670 3627 -  4273 4303 - 
        
Demographics        
Age, years        









  20-49 89 (13.3) 446 (12.3) 0.03  476 (11.2) 530 (12.3) 0.04 
  50-59 105 (15.7) 619 (17.1) 0.04  625 (14.6) 724 (16.8) 0.06 
  60-69 161 (24.0) 951 (26.2) 0.05  1106 (25.9) 1114 (25.9) 0.00 
  70-79 188 (28.1) 1056 (29.1) 0.02  1302 (30.5) 1249 (29.0) 0.03 
  ≥80 127 (19.0) 555 (15.3) 0.10  764 (17.9) 685 (15.9) 0.05 
Race/ethnicity        
  White 256 (38.2) 1347 (37.1) 0.02  1660 (38.9) 1608 (37.4) 0.03 
  Black 291 (43.4) 1649 (45.5) 0.04  1877 (43.9) 1944 (45.2) 0.03 
  Hispanic 74 (11.0) 432 (11.9) 0.03  475 (11.1) 503 (11.7) 0.02 
  Other 22 (3.3) 102 (2.8) 0.03  152 (3.6) 126 (2.9) 0.04 
  Unknown 27 (4.0) 97 (2.7) 0.08  109 (2.6) 122 (2.8) 0.02 
Male sex 620 (92.5) 3395 (93.6) 0.04  4029 (94.3) 4020 (93.4) 0.04 
Urban residence 587 (87.6) 3181 (87.7) 0.00  3823 (89.5) 3777 (87.8) 0.05 
Census region        
  Midwest 79 (11.8) 724 (20.0) 0.22  685 (16.0) 799 (18.6) 0.07 
  Northeast 139 (20.7) 622 (17.1) 0.09  863 (20.2) 764 (17.8) 0.06 
  South 314 (46.9) 1703 (47.0) 0.00  1992 (46.6) 2019 (46.9) 0.01 
  West 138 (20.6) 578 (15.9) 0.12  733 (17.2) 720 (16.7) 0.01 
Month of admission        
  March 116 (17.3) 518 (14.3) 0.08  645 (15.1) 631 (14.7) 0.01 
  April 169 (25.2) 868 (23.9) 0.03  981 (22.9) 1041 (24.2) 0.03 
  May 70 (10.4) 429 (11.8) 0.04  552 (12.9) 499 (11.6) 0.04 
  June 110 (16.4) 616 (17.0) 0.02  721 (16.9) 727 (16.9) 0.00 
  July 205 (30.6) 1196 (33.0) 0.05  1375 (32.2) 1404 (32.6) 0.01 
        
Clinical conditions        
Acute myocardial infarction 11 (1.6) 66 (1.8) 0.01  90 (2.1) 79 (1.8) 0.02 
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Asthma 33 (4.9) 176 (4.9) 0.00  234 (5.5) 210 (4.9) 0.03 
Cancer, any 97 (14.5) 494 (13.6) 0.02  635 (14.9) 595 (13.8) 0.03 
Cerebrovascular disease 85 (12.7) 369 (10.2) 0.08  446 (10.4) 458 (10.7) 0.01 
Chronic kidney disease 136 (20.3) 694 (19.1) 0.03  870 (20.4) 840 (19.5) 0.02 
COPD 105 (15.7) 544 (15.0) 0.02  716 (16.8) 655 (15.2) 0.04 
Coronary artery disease 25 (3.7) 90 (2.5) 0.07  129 (3.0) 118 (2.7) 0.02 
Dementia 104 (15.5) 378 (10.4) 0.15  520 (12.2) 486 (11.3) 0.03 
Diabetes 269 (40.1) 1573 (43.4) 0.07  1714 (40.1) 1845 (42.9) 0.06 
Heart failure 77 (11.5) 375 (10.3) 0.04  529 (12.4) 463 (10.8) 0.05 
Hypertension 446 (66.6) 2470 (68.1) 0.03  2754 (64.5) 2918 (67.8) 0.07 
Liver disease 71 (10.6) 322 (8.9) 0.06  417 (9.8) 397 (9.2) 0.02 
Peripheral arterial disease 70 (10.4) 387 (10.7) 0.01  471 (11.0) 458 (10.6) 0.01 
Charlson Comorbidity Index        
  0 130 (19.4) 765 (21.1) 0.04  807 (18.9) 898 (20.9) 0.05 
  1 110 (16.4) 723 (19.9) 0.09  775 (18.1) 845 (19.6) 0.04 
  2 119 (17.8) 657 (18.1) 0.01  805 (18.8) 767 (17.8) 0.03 
  3 74 (11.0) 394 (10.9) 0.01  502 (11.8) 468 (10.9) 0.03 
  4 69 (10.3) 324 (8.9) 0.05  434 (10.2) 386 (9.0) 0.04 
  ≥5 168 (25.1) 764 (21.1) 0.10  950 (22.2) 938 (21.8) 0.01 
        
Medication history        
ACE inhibitor 119 (17.8) 807 (22.2) 0.11  843 (19.7) 924 (21.5) 0.04 
ARB 78 (11.6) 481 (13.3) 0.05  520 (12.2) 565 (13.1) 0.03 
NSAID 144 (21.5) 731 (20.2) 0.03  814 (19.1) 874 (20.3) 0.03 
Oral corticosteroid 156 (23.3) 875 (24.1) 0.02  1026 (24.0) 1031 (24.0) 0.00 
        
In-hospital treatments         
Dexamethasone        
  Within 24 hours 74 (11.0) 588 (16.2) 0.15  616 (14.4) 662 (15.4) 0.03 
  After 24 hours 115 (17.2) 892 (24.6) 0.18  923 (21.6) 1014 (23.6) 0.05 
Remdesivir        
  Within 24 hours 35 (5.2) 437 (12.0) 0.24  408 (9.5) 471 (10.9) 0.05 
  After 24 hours 89 (13.3) 791 (21.8) 0.23  681 (15.9) 891 (20.7) 0.12 
        
Substance use        
Alcohol 
consumption/disorder        
  Abstinent 51 (7.6) 300 (8.3) 0.02  355 (8.3) 353 (8.2) 0.00 
  Low-risk consumption 360 (53.7) 1831 (50.5) 0.07  2113 (49.4) 2192 (50.9) 0.03 
  At-risk consumption 148 (22.1) 965 (26.6) 0.11  1145 (26.8) 1111 (25.8) 0.02 
  Hazardous consumption 28 (4.2) 161 (4.4) 0.01  157 (3.7) 187 (4.4) 0.03 
  Alcohol use disorder 3 (0.4) 19 (0.5) 0.01  21 (0.5) 22 (0.5) 0.00 
  Missing 80 (11.9) 351 (9.7) 0.07  482 (11.3) 436 (10.1) 0.04 
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Smoking status        
  Never 17 (2.5) 63 (1.7) 0.06  84 (2.0) 82 (1.9) 0.00 
  Former 258 (38.5) 1431 (39.5) 0.02  1502 (35.1) 1681 (39.1) 0.08 
  Current 225 (33.6) 1355 (37.4) 0.08  1805 (42.3) 1583 (36.8) 0.11 
  Missing 170 (25.4) 778 (21.5) 0.09  882 (20.6) 956 (22.2) 0.04 
        
Vital signs        
Body mass index, kg/m2        
  <26 206 (30.7) 938 (25.9) 0.11  1257 (29.4) 1150 (26.7) 0.06 
  26-32 258 (38.5) 1436 (39.6) 0.02  1876 (43.9) 1705 (39.6) 0.09 
  ≥33 169 (25.2) 1113 (30.7) 0.12  986 (23.1) 1271 (29.5) 0.15 
  Missing 37 (5.5) 140 (3.9) 0.08  155 (3.6) 177 (4.1) 0.03 
Oxygen saturation, %        
  <93 72 (10.7) 582 (16.0) 0.16  628 (14.7) 656 (15.2) 0.02 
  93-96 182 (27.2) 1147 (31.6) 0.10  1336 (31.3) 1328 (30.9) 0.01 
  ≥96 396 (59.1) 1775 (48.9) 0.21  2150 (50.3) 2177 (50.6) 0.01 
  Missing 20 (3.0) 123 (3.4) 0.02  160 (3.7) 142 (3.3) 0.02 
Pulse, beats/min        
  <90 438 (65.4) 2200 (60.7) 0.10  2649 (62.0) 2649 (61.6) 0.01 
  ≥90 232 (34.6) 1427 (39.3) 0.10  1624 (38.0) 1653 (38.4) 0.01 
Systolic blood pressure, mm 
Hg        
  <140 446 (66.6) 2360 (65.1) 0.03  2688 (62.9) 2804 (65.2) 0.05 
  ≥140 224 (33.4) 1267 (34.9) 0.03  1585 (37.1) 1499 (34.8) 0.05 
Temperature, °F        
  ≤98.6 356 (53.1) 1701 (46.9) 0.12  2085 (48.8) 2061 (47.9) 0.02 
  98.6-100.3 244 (36.4) 1292 (35.6) 0.02  1471 (34.4) 1538 (35.8) 0.03 
  ≥100.4 70 (10.4) 634 (17.5) 0.20  717 (16.8) 703 (16.3) 0.01 
        
Laboratory findings        
Alanine aminotransferase, 
U/L        
  ≤30 297 (44.3) 1722 (47.5) 0.06  2157 (50.5) 2024 (47.0) 0.07 
  >30 241 (36.0) 1456 (40.1) 0.09  1498 (35.1) 1690 (39.3) 0.09 
  Missing 132 (19.7) 449 (12.4) 0.20  618 (14.5) 588 (13.7) 0.02 
Aspartate aminotransferase, 
U/L        
  ≤30 225 (33.6) 1171 (32.3) 0.03  1432 (33.5) 1400 (32.5) 0.02 
  >30 301 (44.9) 1949 (53.7) 0.18  2108 (49.3) 2244 (52.1) 0.06 
  Missing 144 (21.5) 507 (14.0) 0.20  733 (17.2) 659 (15.3) 0.05 
eGFR, mL/min        
  ≥60 354 (52.8) 2034 (56.1) 0.07  2324 (54.4) 2388 (55.5) 0.02 
  30-59 159 (23.7) 957 (26.4) 0.06  1108 (25.9) 1115 (25.9) 0.00 
  <30 82 (12.2) 418 (11.5) 0.02  547 (12.8) 503 (11.7) 0.03 
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  Missing 75 (11.2) 218 (6.0) 0.19  294 (6.9) 297 (6.9) 0.00 
Glucose, mg/dL        
  ≤170 486 (72.5) 2766 (76.3) 0.09  3264 (76.4) 3250 (75.5) 0.02 
  >170 135 (20.1) 759 (20.9) 0.02  850 (19.9) 897 (20.8) 0.02 
  Missing 49 (7.3) 102 (2.8) 0.21  159 (3.7) 156 (3.6) 0.00 
Hemoglobin, g/dL        
  ≤14 387 (57.8) 2151 (59.3) 0.03  2490 (58.3) 2546 (59.2) 0.02 
  >14 231 (34.5) 1353 (37.3) 0.06  1621 (37.9) 1581 (36.7) 0.02 
  Missing 52 (7.8) 123 (3.4) 0.19  162 (3.8) 175 (4.1) 0.02 
Platelet count, K/µL        
  ≤230 421 (62.8) 2433 (67.1) 0.09  2939 (68.8) 2855 (66.3) 0.05 
  >230 195 (29.1) 1097 (30.2) 0.02  1186 (27.7) 1292 (30.0) 0.05 
  Missing 54 (8.1) 97 (2.7) 0.24  149 (3.5) 156 (3.6) 0.01 
White blood cell count, K/µL        
  ≤6 299 (44.6) 1747 (48.2) 0.07  2071 (48.5) 2047 (47.6) 0.02 
  >6 319 (47.6) 1786 (49.2) 0.03  2058 (48.2) 2105 (48.9) 0.02 
  Missing 52 (7.8) 94 (2.6) 0.24  144 (3.4) 152 (3.5) 0.01 
Lymphocyte count, K/µL        
  ≤0.6 100 (14.9) 600 (16.5) 0.04  705 (16.5) 702 (16.3) 0.01 
  >0.6 431 (64.3) 2523 (69.6) 0.11  2851 (66.7) 2951 (68.6) 0.04 
  Missing 139 (20.7) 504 (13.9) 0.18  717 (16.8) 650 (15.1) 0.05 
Total cholesterol, mg/dL        
  ≤130 152 (22.7) 678 (18.7) 0.10  794 (18.6) 826 (19.2) 0.02 
  >130 415 (61.9) 2444 (67.4) 0.11  2815 (65.9) 2864 (66.6) 0.01 
  Missing 103 (15.4) 505 (13.9) 0.04  665 (15.6) 613 (14.2) 0.04 
HDL cholesterol, mg/dL        
  <38 180 (26.9) 917 (25.3) 0.04  1099 (25.7) 1093 (25.4) 0.01 
  38-49 202 (30.1) 1213 (33.4) 0.07  1434 (33.6) 1418 (33.0) 0.01 
  ≥50 181 (27.0) 988 (27.2) 0.01  1067 (25.0) 1171 (27.2) 0.05 
  Missing 107 (16.0) 509 (14.0) 0.05  672 (15.7) 621 (14.4) 0.04 
LDL cholesterol, mg/dL        
  <30 58 (8.7) 310 (8.5) 0.00  350 (8.2) 366 (8.5) 0.01 
  60-89 133 (19.9) 628 (17.3) 0.07  723 (16.9) 768 (17.9) 0.02 
  ≥90 370 (55.2) 2165 (59.7) 0.09  2514 (58.8) 2531 (58.8) 0.00 
  Missing 109 (16.3) 524 (14.4) 0.05   686 (16.1) 638 (14.8) 0.03 
Abbreviations: COVID-19, coronavirus disease 2019; IPT, inverse probability of treatment; SMD, absolute value 
of the standardized mean difference; COPD, chronic obstructive pulmonary disease; ACE, angiotensin converting 
enzyme; ARB, angiotensin II receptor blocker; NSAID, non-steroidal anti-inflammatory drug; eGFR, estimated 
glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein 
Note: Reported as n(%) unless otherwise specified 
 
 
In this cohort, 3,627 (84.4%) patients received prophylactic anticoagulation within the first 24 
hours of hospital admission. Among those who received prophylactic anticoagulation, the most 
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common drugs were heparin-based: either subcutaneous heparin (n=1,094, 30.2%) or 
enoxaparin (n=2,506, 69.1%; Box 1 in the Supplementary Appendix).  
 
At hospital presentation, the group of patients who received prophylactic anticoagulation, 
compared to the group of patients who did not, had a higher proportion with an oxygen 
saturation level less than 93% (Table 1; 16.0% versus 10.3%), heart rate at 90 beats per minute 
or above (39.2% versus 34.5%), and temperature of 100.4 degrees Fahrenheit or above (17.5% 
versus 10.6%). In contrast, the burden of prevalent comorbid disease (Charlson Comorbidity 
Index ≥5) was lower among those who received prophylactic anticoagulation as compared to 
those that did not (21.1% versus 25.1%, respectively). Co-medication with other COVID-19 
treatments within the first 24 hours of admission were more common among those who received 
prophylactic anticoagulation compared to those who did not (16.2% versus 11.0% for 
dexamethasone; 12.0% versus 5.2% for remdesivir). However, after IPT-weighting, differences 
were minimized between the two treatment groups (all standardized mean differences ≤0.2 with 
vast majority ≤0.1; Table 1). 
 
Absolute and relative risks 
There were 622 deaths (622/4297, 14.5%) that occurred within 30 days of hospital admission, 
513 among those who received prophylactic anticoagulation (Table 2). Most deaths (510/622, 
82%) occurred during hospitalization. In IPT-weighted analyses, cumulative adjusted incidence 
of mortality at 30 days was 14.3% (95% CI 13.1-15.5) and 18.7% (95% CI 15.1-22.9) for 
patients receiving and not receiving prophylactic anticoagulation, respectively (Table 2). Receipt 
of prophylactic anticoagulation was associated with a 27% decreased risk of death over the first 
30 days (HR 0.73, 95% CI 0.66-0.81; Figure 3) compared to not receiving prophylactic 
anticoagulation. Similar associations were found for inpatient mortality (HR 0.69, 95% CI 0.61-
0.77) and initiating therapeutic anticoagulation (HR 0.81, 95% CI 0.73-0.90). 
 
Table 2. Absolute and relative risks associated with exposure to prophylactic doses of anticoagulation in the first 
24 hours of hospitalization 
   Unweighted  IPT-weighted 
Outcome N 
No. 
events HR (95% CI)   
Cumulative 
incidence (95% CI) HR (95% CI) 
30-day mortality       
  Exposed 3627 513 0.85 (0.69-1.05)  14.3 (13.1-15.5) 0.73 (0.66-0.81) 
  Unexposed 670 109 ref  18.7 (15.1-22.9) ref 
Inpatient mortality       
  Exposed 3627 418 0.82 (0.66-1.03)  11.7 (10.7-12.8) 0.69 (0.61-0.77) 
  Unexposed 670 92 ref  16.4 (13.0-20.5) ref 
Initiate therapeutic 
anticoagulation      
  Exposed 3627 573 1.14 (0.91-1.42)  15.6 (14.4-16.8) 0.81 (0.73-0.90) 
  Unexposed 670 92 ref   18.8 (15.2-23.1) ref 




Figure 3. Inverse probability treatment-weighted Kaplan-Meier plots
Abbreviations: AC, prophylactic anticoagulation
(b) Inpatient mortality
(a) 30-day mortality
(c) Initiate therapeutic anticoagulation
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Sensitivity analyses 
Quantitative bias analysis demonstrated that an unmeasured confounder would need to be 
strongly associated with receipt of prophylactic anticoagulation and each outcome to explain the 
observed associations: e-value lower 95% CI was 1.77 for 30-day mortality, 1.92 for inpatient 
mortality, and 1.46 for initiating therapeutic anticoagulation (eFigure 3). Results were robust to 
capping propensity scores (eTable 1), using stabilized weighting and robust variance estimation 
(eTable 2), extending the exposure window from 24 to 48 hours (eTable 3), and excluding 
DOACs from the exposure definition (eTable 4). In post-hoc analyses, the effect of prophylactic 
anticoagulation on 30-day mortality was similar when stratified by whether patients received 
subcutaneous heparin (HR 0.73, 95% CI 0.64-0.84) or enoxaparin (HR 0.78, 95% CI 0.68-0.89; 




In a nationwide cohort of 4,297 patients hospitalized with COVID-19 in the largest integrated 
healthcare system in the United States, initiation of predominantly heparin-based prophylactic 
anticoagulation within the first 24 hours of admission was associated with a relative risk 
reduction of 30-day mortality as high as 34% and an absolute risk reduction of 4.5% in the 
context of an absolute risk of 18.7% among patients who did not receive prophylactic 
anticoagulation. These results persisted in sensitivity analyses. We observed similar protective 
effects for secondary outcomes including inpatient mortality and initiation of therapeutic 
anticoagulation - a proxy for the development of a thromboembolic event.  
 
Comparison with other evidence 
Previous studies investigating the role of anticoagulation among patients with COVID-19 have 
had varied results, but none have reported harm.11,12,25–32 Variations in reported associations 
likely derive from different exposure definitions of anticoagulation, both form and dose. 
Additionally, different patient populations (e.g., disease-specific cohorts), comparator groups, 
and inclusion/exclusion criteria were used. One of the largest observational studies to date by 
Nadkarni et al reported that both prophylactic and therapeutic anticoagulation were associated 
with a reduction in inpatient mortality by up to 55% compared to those not receiving 
anticoagulation across five New York City hospitals.11 However, the study allowed patients to 
switch exposure groups during follow-up without comprehensively accounting for time-updated 
confounding by indication that may have impacted results.  
 
Our study was designed to emulate a hypothetical clinical trial in which we excluded prevalent 
users of anticoagulation, balanced covariate distribution at hospital admission (analogous to 
randomization) and ascertained exposure within 24 hours of admission. We conducted an 
intention-to-treat analysis since the data required to account for time-updated exposures and 
confounders (e.g., marginal structural modeling) may not be available within acute 
hospitalizations. For example, many hospital systems report all diagnoses that occur during a 
given hospitalization at discharge. Therefore, we could not determine if initiation of prophylactic 
anticoagulation later in hospitalization confers benefit. There are multiple clinical trials in 
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progress to determine dosing and timing for anticoagulation during the clinical course of COVID-
19.10 Until clinical trial data are available, our results provide strong evidence for the use of 
prophylactic anticoagulation as initial therapy for COVID-19 patients upon hospital admission. 
 
Thromboembolic events in the context of COVID-19 are strongly associated with 
mortality.3,25,31,33,34 The etiology of heightened thrombosis remains unclear, although proposed 
mechanisms have included systemic inflammation, endothelialitis, and activation of the 
complement system.35–37 Increases in a variety of inflammatory pathways, including bradykinin, 
interleukin-6, C-reactive protein, and growth differentiation factor 15, have been described in 
COVID-19.8,9,38–47 Further, heparin has been shown to block SARS-CoV-2 viral spike protein 
binding in experimental studies.48–50 We postulate that the combination of heparin’s known 
antithrombotic and anti-inflammatory effects,6,7 in addition to viral infectivity attenuation may, at 
least in part, explain the observed benefit associated with prophylactic anticoagulation.  
 
Strengths and limitations 
While this study had many strengths, including the availability of detailed, longitudinal, electronic 
health record data on a nationwide cohort of patients hospitalized with COVID-19, rigorous 
methodology and findings that were robust to sensitivity analyses, we recognize possible 
limitations. First, due to the observational nature of the study, a degree of uncertainty persists 
that can only be addressed through randomized trials. Nonetheless, we took several steps to 
mitigate potential confounding. We comprehensively accounted for chronic and acute health 
conditions at hospital admission in addition to other potential COVID-19 treatments to achieve 
balance of these potential confounders between treatment groups. Further, we showed that our 
results were robust to unmeasured confounding using quantitative bias analysis, which 
demonstrated that a confounder would need to be strongly associated with receipt of 
prophylactic anticoagulation and each of the outcomes considered to explain the observed 
effects. Second, we did not have available a validated algorithm to identify thromboembolic 
events as an outcome. However, the use of therapeutic anticoagulation may occur as a result of 
many reported complications of COVID-19 including venous thromboembolism, arterial 
thromboembolism, cardiac arrhythmia, and disseminated intravascular coagulation.51–58 We 
surmised that an intensification of anticoagulation indicated an adverse change in clinical 
condition. Third, this study was conducted on Veterans currently receiving care in the VA, who 
are older and have a higher prevalence of chronic health conditions and risk behaviors than the 
general US population.59–61 However, prior research has established that after adjusting for age, 
sex, race/ethnicity, region, and rural/urban residence, all of which were accounted for in this 
study, there is no difference in total disease burden between Veterans and non-Veterans.61 Our 
key finding has also been shown in non-Veteran populations;11,12 thus, effects reported in this 
study are likely generalizable to the wider US population. Fourth, while individuals in VA care 




We studied a nationwide cohort of patients hospitalized with COVID-19 and found that initiation 
of prophylactic, heparin-based anticoagulation within 24 hours of admission was associated with 
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a lower risk of 30-day mortality, in-hospital mortality, and initiation of therapeutic-dose 
anticoagulation likely indicative of a thromboembolic event. Our results provide strong real-world 
evidence to support guidelines recommending the use of prophylactic anticoagulation as initial 
therapy for COVID-19 patients upon hospital admission.  
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